LAVAL, QC, Oct. 19 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS)
today announced that it will host a conference call on Thursday, October 28,
2004 at 8:30 a.m. (ET) to discuss its third quarter fiscal 2004 results.
Labopharm will report its third quarter fiscal 2004 results via news release
at approximately 7:00 a.m. the same day.
To access the conference call by telephone, dial 416-405-9328 or
1-800-387-6216. Please connect approximately fifteen minutes prior to the
beginning of the call to ensure participation. The conference call will be
archived for replay until Thursday, November 4, 2004 at midnight. To access
the archived conference call, dial 416-695-5800 or 1-800-408-3053 and enter
the reservation number 3106764 followed by the number sign.
A live audio webcast of the conference call will be available at
www.labopharm.com and www.financialdisclosure.ca. Please connect at least
15 minutes prior to the conference call to ensure adequate time for any
software download that may be required to join the webcast. The webcast will
be archived at the above web sites for 90 days.
About Labopharm Inc.
Labopharm Inc. (TSX:DDS) is an international specialty pharmaceutical
company focused on the development of drugs incorporating the Company's
proprietary advanced controlled-release technology, Contramid(R). Contramid(R)
can be applied to a wide variety of drugs in solid oral dosage form, improving
their oral administration and performance, and is used to develop products
that are either bio-equivalent to existing, branded products, or are new
branded products. The Company's pipeline includes a combination of both
in-house and partnered programs with products both in clinical trials and in
preclinical development. Labopharm is also developing novel polymeric
nano-delivery systems for delivery of water-insoluble and poorly bio-available
drugs. For more information, please visit www.labopharm.com.
This press release contains forward-looking statements, which reflect the
Corporation's current expectations regarding future events. The
forward-looking statements involve risks and uncertainties. Actual events
could differ materially from those projected herein and depend on a number of
factors, including the successful and timely completion of clinical studies,
the uncertainties related to the regulatory process and the commercialization
of the drug thereafter. Investors should consult the Corporation's ongoing
quarterly filings and annual reports for additional information on risks and
uncertainties relating to these forward-looking statements. The reader is
cautioned not to rely on these forward-looking statements. The Corporation
disclaims any obligation to update these forward-looking statements.
SOURCE Labopharm Inc.